Turku PET Centre
Welcome,         Profile    Billing    Logout  
 29 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jyrkkiö, Sirkku
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
300
Europe, RoW
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
12/25
12/28
Knuuti, Juhani
DECADE, NCT04290091: Detection of Coronary Artery Disease With Micro Electro-Mechanical Sensors

Active, not recruiting
N/A
930
Europe
Precordior Ltd
Coronary Artery Disease
12/21
12/23
Rinne, Juha
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
NCT05328115: A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease

Recruiting
1
33
Europe
ALZ-101, Placebo
Alzinova AB, CRST Oy
Alzheimer Disease, Dementia Alzheimers, Dementia, Mild
01/25
01/25
NCT06659562: Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients with Parkinson's Disease

Recruiting
1
40
Europe
HER-096, Placebo, Sodium chloride 9 mg/ml, 0.9% physiological saline solution
Herantis Pharma Plc., Clinical Research Services Turku - CRST Ltd, BC Platforms, Oy Medfiles Ltd
Parkinson Disease, Idiopathic
09/25
12/25
Nuutila, Pirjo
AM05, NCT05132335: A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects

Completed
N/A
19
Europe
Imaging Biomarkers, Assessment of repeatability of fatty acid uptake in adipose using PETMRI
Turku University Hospital, Antaros Medical
Diabetes Mellitus, Type 2
11/21
04/22
Koffert, Jukka P
No trials found
Hyypia, Aino
No trials found
Laurila, Sanna
No trials found
Monfort-Pires, Milena
No trials found
Airas, Laura
No trials found
Acosta, Francisco
No trials found
Heinonen, Ilkka H
No trials found
Hannukainen, Jarna C
No trials found
Virtanen, Kirsi A
No trials found
Kemppainen, Jukka
No trials found
Malaspina, Simona
No trials found
Nystrand, Ilja
No trials found
Rissanen, Eero
No trials found
Kalliokoski, Kari K
No trials found
Eskelinen, Joonas J
No trials found
Savolainen, Anna
No trials found
Pärkkä, Jussi
No trials found
Lepomäki, Virva
No trials found
Parkkola, Riitta
No trials found
Kallio, Petri
No trials found
Himanen, Sanna
No trials found
Karukivi, Max
No trials found
U-Din, Mueez
No trials found
Ekblad, Laura
No trials found
Rebelos, Eleni
No trials found
Nummenmaa, Lauri
No trials found

Download Options